Design and synthesis of GRPR-targeted PET probes based on Dar derivatives for imaging of prostate cancer
Nanomedicine: Nanotechnology, Biology and Medicine · 2025
DOI: 10.1016/j.nano.2025.102829 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nanomedicine: Nanotechnology, Biology and Medicine, 2025. Verfasst von Xiangning Luo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Innovative Drug Research Center, Shanghai University, Shanghai 200444, China; State Key Laboratory of Drug Research, Molecul…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Receptors, Bombesin, Radiopharmaceuticals, Positron Emission Tomography Computed Tomography. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Chinese Academy of Sciences, State Key Laboratory of Drug Research, Chinese Academy of Sciences, National Natural Science Foundation of China.
Abstract (Originalsprache)
Gastrin-releasing peptide receptor (GRPR) is overexpressed in most prostate cancers (PCa) and is a potential target in diagnosis and treatment. In this study, based on the previously reported GRPR antagonist RM26 and novel chelating agent Dar derivatives, we designed and evaluated two radiopharmaceuticals, [68Ga]Ga-Dar-C5-P2-RM26 and [68Ga]Ga-Dar-P2-RM26. Both radiotracers were easily prepared at room temperature and showed high radiochemical stability in phosphate-buffered saline (PBS) and fetal bovine serum (FBS). Cellular and animal experiments indicated that the two radiotracers exhibited specific tumor uptakes in PC-3 xenograft mice models. Specifically, [68Ga]Ga-Dar-C5-P2-RM26 and [68Ga]Ga-Dar-P2-RM26 displayed 6.617 ± 0.245 % ID/g and 5.973 ± 1.261 % ID/g tumor uptake, respectively. Positron emission tomography/ computer tomography (PET/CT) imaging results indicated that these two radiotracers showed excellent tumor-to-background contrast at 0.5 h, 1 h, and 2 h post intravenous injection (p.i.). In summary, [68Ga]Ga-Dar-C5-RM26 and [68Ga]Ga-Dar-RM26 are GRPR-targeted radiotracers with high potential for clinical translation in tumor-targeted imaging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Innovative Drug Research Center, Shanghai University, Shanghai 200444, China; State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Acade…
- State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
- State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; School of Pharmacy, University of Chinese Academy of Sciences,…
- Department of Nuclear Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200235, China. Electronic address: caorui6th@sjtu.edu.cn.
- Department of Chemistry, Innovative Drug Research Center, Shanghai University, Shanghai 200444, China. Electronic address: xubin@shu.edu.cn.
Förderung
- Chinese Academy of Sciences
- State Key Laboratory of Drug Research, Chinese Academy of Sciences
- National Natural Science Foundation of China
Zitieren
APA
Luo, X., Luo, R., Zhou, Y., Jiang, Y., Han, C., Song, A., Qian, K., Qu, C., Cao, R., Xu, B., & Cheng, Z. (2025). Design and synthesis of GRPR-targeted PET probes based on Dar derivatives for imaging of prostate cancer. Nanomedicine: Nanotechnology, Biology and Medicine. https://doi.org/10.1016/j.nano.2025.102829
Vancouver
Luo X, Luo R, Zhou Y, Jiang Y, Han C, Song A, et al. Design and synthesis of GRPR-targeted PET probes based on Dar derivatives for imaging of prostate cancer. Nanomedicine: Nanotechnology, Biology and Medicine. 2025. doi:10.1016/j.nano.2025.102829
BibTeX
@article{Luo2025,
author = {Luo, Xiangning and Luo, Renli and Zhou, Yuanyuan and Jiang, Yuanpeng and Han, Cong and Song, Aiguo and Qian, Kun and Qu, Chunrong and Cao, Rui and Xu, Bin and Cheng, Zhen},
title = {Design and synthesis of GRPR-targeted PET probes based on Dar derivatives for imaging of prostate cancer},
journal = {Nanomedicine: Nanotechnology, Biology and Medicine},
year = {2025},
doi = {10.1016/j.nano.2025.102829}
}
EUVIMED